Company announcement no. 12-2019   


Birkerød, 3 September 2019

 

ViroGates A/S (Nasdaq First North Growth Market Denmark: VIRO), who delivers blood test systems, primarily for acute care departments in hospitals, today announces that suPARnostic® now will be available for clinical decision making in the University Hospital of Montpellier, France. The hospital will be the first hospital in the world to run suPARnostic® TurbiLatex at the Roche cobas 8000 system.
The Hospital has initially been using the suPARnostic® TurbiLatex product to predict outcome in patients with chronic- or acute heart failure. The results have been evaluated with other biomarkers that are specific to this clinical condition and also physiological scores that are typically used to assess the risk of the individual patient and determine the best program for follow up.
There is a big demand for better prognostication of heart failure patients given that many have follow on complications after the initial treatment.
The implementation of the suPARnostic® TurbiLatex product was conducted by Dr Anne-Marie Dupuy in the Laboratory of Biochemistry and Hormonology, which is headed by Professor Jean Paul Cristol.
The laboratory has a 24/7 days service for blood samples from all departments within the hospital and runs approx. 500,000 blood samples annually and suPARnostic® TurbiLatex will now be available for all departments in the hospital including the Emergency Department.

Professor Jean Paul Cristol saysWe see an increasing need for better prognostication of patients in all areas of medicine but particularly within cardiovascular diseases. Biomarkers are very important to guide treatment and follow up programs for patients. We are happy to break new ground by being the first hospital in the world to implement suPARnostic® TurbiLatex on the cobas 8000 system and due to our vast experience with new assays the application of this product went very smooth. We look forward to work with ViroGates to allow for better treatment of patients here at the hospital.”
  
CEO Jakob Knudsen, says in a comment: ”We are very pleased to see the first effects of our direct sales initiatives in France and to be able to announce such a highly scientifically accredited customer as the Laboratory of Biochemistry and Hormonology at the University Hospital of Montpellier as our first customer for the suPARnostic® TurbiLatex cobas 8000 module. It has been a pleasure to work with Professsor Cristol and his team to set up the assay at the cobas module and we are confident that this work will lead to more hospitals in France as future customers.”

The announcement can be found at https://www.virogates.com/investor/announcements 

For further information contact:
CEO Jakob Knudsen
Tel. (+45) 2113 1336, Email: jk@virogates.com

ViroGates A/S
CVR-nr. 25734033
Blokken 45, DK-340 Birkerød
www.virogates.com

Certified Advisor
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, Email: per.lonn@vhcorp.se

About ViroGates
ViroGates is an international Medtech company headquartered in Denmark. ViroGates develops and sells prognostic products to the healthcare sector. The products are used in hospital emergency services, in particular to make a clinical decision on hospitalization or discharge of emergency patients, which can lead to better clinical decisions, faster discharge and optimization of healthcare resources. The products can also be used for the prognosis of lifestyle-related diseases such as cardiovascular disease, type 2 diabetes, cancer, etc. The ViroGates test suPARnostic® measures the suPAR (Soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream, and with the suPARnostic® Quick Triage test, hospital staff will get answers in just 20 minutes. The prognostic value of suPARnostic® is validated by more than 550 clinical trials and studies which included more than 350,000 blood samples.

Attachment